Polycyclic guanine phosphodiesterase V inhibitors

Details Polycyclic guanine phosphodiesterase V inhibitors Polycyclic guanine phosphodiesterase V inhibitors

2005-11-29

2005-11-29

McKenzie, Thomas C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S267000, C544S230000, C544S247000, C544S251000

Reexamination Certificate

active

06969719

ABSTRACT:
A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders:A representative example is:

REFERENCES:
patent: 5321029 (1994-06-01), Maschler et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5409934 (1995-04-01), Smith et al.
patent: 5470579 (1995-11-01), Bonte et al.
patent: 5637593 (1997-06-01), Porter et al.
patent: 5824683 (1998-10-01), McKittrick et al.
patent: 5939419 (1999-08-01), Tulshian et al.
patent: 5955611 (1999-09-01), Dunn et al.
patent: 5981563 (1999-11-01), Lowrey
patent: 6023640 (2000-02-01), Ross
patent: 6037346 (2000-03-01), Doherty, Jr. et al.
patent: 6051594 (2000-04-01), Lowrey
patent: 6066735 (2000-05-01), Dunn et al.
patent: 6087362 (2000-07-01), El-Rashidy
patent: 6100270 (2000-08-01), Campbell
patent: 6140329 (2000-10-01), Daugan
patent: 6403597 (2002-06-01), Wilson et al.
patent: 2002/0091129 (2002-07-01), Boolell
patent: P 19 38 016.6 (1971-01-01), None
patent: 0 258 191 (1988-03-01), None
patent: 0 389 282 (1990-09-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0702555 (1998-11-01), None
patent: 2 116 302 (1972-07-01), None
patent: WO 91/07945 (1991-06-01), None
patent: WO 91/07945 (1991-06-01), None
patent: WO91/19717 (1991-12-01), None
patent: WO 91 19717 (1991-12-01), None
patent: WO 92/05175 (1992-04-01), None
patent: WO 92/05176 (1992-04-01), None
patent: WO 93/23401 (1993-11-01), None
patent: WO 94 19351 (1994-09-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 99/24433 (1999-05-01), None
patent: WO 99/54331 (1999-10-01), None
patent: WO 99/54331 (1999-10-01), None
patent: WO 99/62905 (1999-12-01), None
David J.W. Grant, “University of Minnesota—Twin Cities Campus College of Pharmacy, Annual Report”, [online] 1999, [retrieved on Feb. 13, 2003]. Retrieved from the internet, <http://www.msi.umn.edu/general/Reports/ar99/departments/pharmacy.html>.
Gavazzotti, Angelo, Acc. Chem. Res., 1994, 27, 309-314.
West, Anthony R., “Solid State Chemistry and its Applications”, Wiley, New York, 1988, pp. 358 & 365.
Perry, M.J. et al, Current Opinion in Chemical Biology, 1998, 2, 472-481.
Corbin JD, Francis SH., Int J Clin Pract. Jul.-Aug. 2002;56(6):453-9.
Cremers B, Bohm M., Herz. Jun. 2003;28(4):325-33.
Bortolotti, M., et al, “Effect of Sildenafil on hypertensive lower oesophageal sphincter”, European Journal of Clinical Investigation, vol. 32, pp. 682-685, (2002).
Eherer, A J., et al, “Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesphageal motor disorders”, GUT, vol. 50, pp. 758-764, (2002).
Ghofrani, Hossein A., et al, “Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension”, Annals of Internal Medicine, vol. 136, No. 7, pp. 515-522, (2002).
Ghofrani, Hossein A., et al, “Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension”, American Journal of Respiratory and Critical Care Medicine, vol. 167, pp1139-1141, (2003).
Ghofrani, Hossein A., et al, “Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial”, The Lancet, vol. 360, pp. 895-900, (2002).
Inoha, Satoshi, et al, “Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model”, Neurological Research 2002, vol. 24, pp. 607-612, (2002).
Koppiker, Nandan, “Use of Cgmp PDE5 inhibitors in the treatment of neuropathy: A review of the patent literature”, Idrugs, vol. 5 (5), pp. 448-453, (2002).
Rotella, D., “Phosphodiesterase 5 Inhibitors: Current Status and Potential Applications”, Nature, vol. 1, pp. 674-682, (2002).
Zhang, Ruilan, M.D. et al, “Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats”, Stroke, pp. 2675-2680, (2002).
Ho-Sam Ahn, et al, “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Hypertensive Activity,”Journal of Medicinal Chemistry, vol. 40, No. 14, pp. 2196-2210 (1997).
D. Doller, et al, “The Gif System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG Conditions,”Bioorganic and Medicinal Chemistry Letters, vol. 7, No. 11, pp. 1381-1386 (1997).
J. Shimada, et al, “A Convenient Synthesis of Tricyclic Purine Derivatives,”Journal of Heterocyclic Chemistry, vol. 30, No. 1, pp. 241-246 (1993).
S. Vemulapalli, et al, “Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor,”Journal of Cardiovascular Pharmacology, vol. 28, pp. 862-869 (1996).
International Search Report, based on PCT/US 02/27181, Jan. 13, 2003.
Ahn, Ho-Sam, et al, “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”,J. Med. Chem., Vol. 40, No. 14, pp. 2196-2210 (1997).
International Search Report, PCT/US 02/35721, Feb. 13, 2003.
Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation.American Journal Respir. Crit. Care Med., vol. 160:858-865.
Gaine S.P., et al., (1998) Primary Pulmonary Hypertension.The Lancet, vol. 352:719-725.
Hanasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Pulmonary Hypertension in Rats.American Journal of Physiol., vol. 277 (Lung Cell. Mol. Physiol. 21:L225-L232.
Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 5 Inhibitor, Potentiates the Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs.Journal of Cardiovascular Pharmacology, vol. 33:619-624.
Murray, K.J., Phosphodiesterase V Inhibitors, DN&P 6(3), pp. 150-155, Apr. 1993.
Nantka-Namirski, P. et al.,Synteza 7-Podstawionych Pochodnych 8-aminometylo-1,3-Dwumetloksantyny, Acia, Polan, Pharm. XXX1 Nr 1, (1974) [in Polish].
Nantka-Namirski, P. et al.,Synthesis of 7-Subtituted Deviates of 8-aminomethyl-1,3-dimethylxanthine, Acta. Polon, Pharma. 31(1):5-11 (1974) [English translation].
T. Katsushima et al.,Structure-Activity Relationships of 8-Cycloalkyl-1,3-diprophylxanthines as Antagonists of Adenosine Receptors, J. Med. Chem. 1990, 33, pp. 1906-1910.
XP-002188426, Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines, 6001 Chemical Abstracts, Columbus, Ohio, US, No. 106:95577n, (1987).
Yoneda, F. et al., A New Synthesis of Substituted 8-Aminopurine Derivatives, Bulletin of the Chemical Society of Japan, vol. 46, pp. 1836-1839 (1973).
Youssef, S. et al., Purines XIV.[1] Reactivity of 8-Bromo-3-9-dimethylxanthine Towards Some Nucleophilic Reagents,J. Heterocyclic Chem., 35, 949 (1998).
Remingtons's Pharmaceutical Sciences, 18thEd.,Mack Publishing Co., pp. 1288-1300 (1990).
Handbook of Pharmaceutical Excipients,American Pharmaceutical Association&the Pharmaceutical Society of Great Britain, pp. 81-90 (1986).
Physician's Desk Reference, 55thEd, pp. 2534-2537 (2001).

Affiliated with

Also associated with

Rating

Polycyclic guanine phosphodiesterase V inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polycyclic guanine phosphodiesterase V inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polycyclic guanine phosphodiesterase V inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3484193